WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc., (Pink Sheets:NNVC), officials announced today that they have signed a Cooperative Research and Development Agreement, or CRADA, with the Walter Reed Army Institute of Research (http://wrair-www.army.mil/). The joint R&D effort will focus on creating new treatments for dengue fever using NanoViricides’ virus-killing nanomedicine technology. "This collaboration will leverage Walter Reed’s extensive experience in dengue fever research with our unique nanoviricide™ technology platform for creating anti-viral medications," said NanoViricides’ President Dr. Anil Diwan.
